Northern California Business Development Director Daniels HealthNorthern California Business Development DirectorSan Francisco, CA$90,077–$130,174 / yearThe compensation offered will take into account internal equity and may vary depending on the candidate's geographic region, job-related knowledge, skills, and experience among other factors. Through cutting-edge innovation, infection control expertise, and a fierce commitment to sustainability, we're redefining what it means to protect frontline workers and the environment.
Associate Director, Clinical Biomarker Development Revolution Medicines, Inc.Associate Director, Clinical Biomarker DevelopmentRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline.
Director, Portfolio Omnichannel (Lung Hcp) Revolution Medicines, Inc.Director, Portfolio Omnichannel (Lung Hcp)Redwood City, CA$211,000–$264,000 / yearThe Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Statistical Programming Revolution Medicines, Inc.Associate Director, Statistical ProgrammingRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function.
Director Of IT BillionToOneDirector Of ITUnion City, CA$214,369–$267,962 / yearAt BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. Unity Confirm enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne's Fetal Cell Capture Technology.
Director, Clinical Study Management Eikon Therapeutics, Inc.Director, Clinical Study ManagementMillbrae, CA$226,000–$273,000 / yearThis role will require a minimum of 3 days a week of onsite presence (or more as business needs require) in either of our Jersey City, New Jersey or Millbrae, California offices to ensure effective management and high-performance delivery of clinical studies. The Director will manage all aspects of clinical operations study management for assigned Eikon clinical studies, and be responsible for exquisite inhouse execution of all such clinical trials and oversight of requisite clinical vendors.
Associate Director, Environmental Health And Safety Revolution Medicines, Inc.Associate Director, Environmental Health And SafetyRedwood City, CA$186,000–$233,000 / yearManage occupational health program activities in partnership with internal stakeholders and external providers, including workplace injury and illness investigation and tracking, animal allergen questionnaire administration and follow-up, hepatitis B vaccination program support, ergonomics program coordination and continuous improvement, and maintenance of related documentation, metrics, and compliance records. Support Facilities Safety Programs through cross-functional collaboration and subject matter expertise, ensuring effective implementation of programs such as electrical safety, lockout/tagout, fall protection, confined space, heat illness prevention, and hot work, while maintaining clear role distinction from program ownership.
Senior Director, Compliance Training Revolution Medicines, Inc.Senior Director, Compliance TrainingRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner closely with Learning & Development, Corporate Communications, Legal, HR, regional compliance staff (U.S., Europe, and Asia), and business stakeholders to ensure effective deployment, localization, communication, and reinforcement of training programs.
Associate Director, Biostatistics Clinical Late Stage Revolution Medicines, Inc.Associate Director, Biostatistics Clinical Late StageRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Head Of Transactions & Partnering Revolution Medicines, Inc.Senior Director, Head Of Transactions & PartneringRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role partners closely with Business Development leadership and cross-functional stakeholders across Research, Development, Commercial, Finance, Legal, Intellectual Property, and Executive Management to advance high-priority opportunities from initial assessment through successful execution.
Director, Clinical Data Management Revolution Medicines, Inc.Director, Clinical Data ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Business Operations Revolution Medicines, Inc.Associate Director, Business OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role is ideal for a Associate Director -level professional who thrives on execution, can drive several projects in parallel, can navigate a matrix environment, and brings strong project leadership, communication and change management experience.
Director, Molecular Pathology, Translational Sciences, Translational Research. Revolution Medicines, Inc.Director, Molecular Pathology, Translational Sciences, Translational Research.Redwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies.
Senior Director, US Compliance Revolution Medicines, Inc.Senior Director, US ComplianceRedwood City, CA$244,000–$305,000 / yearAreas of focus include: Serve as the strategic compliance advisor to Commercial, Medical Affairs, Market Access, Patient Services, and other field-facing functions by proactively identifying compliance risks, enabling compliant business solutions, and embedding compliance into key business decisions throughout commercialization and product launch. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Regulatory Affairs Companion Diagnostics (Cdx) Revolution Medicines, Inc.Director, Regulatory Affairs Companion Diagnostics (Cdx)Redwood City, CA$211,000–$264,000 / yearRequired Skills, Experience and Education: Advanced degree or bachelor's degree in life sciences, molecular biology, biomedical engineering, pharmacy, medicine, or related scientific discipline with a minimum of 12+ years of pharmaceutical, biotechnology, diagnostics, or combination product experience, including at least 8 years in Regulatory Affairs supporting companion diagnostics or in vitro diagnostics. This individual will serve as the regulatory lead for companion diagnostic development programs, partnering closely with Clinical Development, Translational Medicine, Biomarker Sciences, Regulatory Science, Commercial, and external diagnostic partners to ensure successful co-development and global registration of therapeutic products and associated companion diagnostics.
Senior Director, Head Of Search & Evaluation Revolution Medicines, Inc.Senior Director, Head Of Search & EvaluationRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Working in close partnership with leaders across Research, Development, Commercial, Corporate Strategy, Portfolio Management, and Executive Management, this individual will lead the company's search and evaluation activities across discovery and clinical-stage opportunities.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Sr. Manager / Associate Director, Quality Audits Personalis, IncSr. Manager / Associate Director, Quality AuditsFremont, CA$165,000–$210,000 / yearReporting directly to the Director of Quality Assurance, this individual is responsible for the strategic oversight, design, and execution of the global Internal Audit program, as well as leading the readiness and management of all External Audits (including regulatory inspections and accreditation assessments).The successful candidate will have strong leadership skills and possess extensive experience managing Quality Management Systems (QMS) within highly regulated environments, driving compliance, governance, and continuous improvement across the organization with a high degree of autonomy. Root Cause & Investigation Leadership: Provide expert guidance and lead cross-functional investigation teams in executing comprehensive root cause analyses for CAPAs, deviations, and non-conformances stemming from internal and external audits.
Associate Director, Global Omnichannel Solutions Delivery Revolution Medicines, Inc.Associate Director, Global Omnichannel Solutions DeliveryRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation.